Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

X
Trial Profile

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Mipasetamab uzoptirine (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Cervical cancer; Chondrosarcoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 06 May 2024 According to an ADC Therapeutics media release, additional data updates from the Phase 1 study in patients with sarcoma, pancreatic cancer and NSCLC expected in 2H 2024
    • 17 Apr 2024 Planned number of patients changed from 196 to 260.
    • 13 Mar 2024 According to an ADC Therapeutics media release, additional data updates from the Phase 1 study in patients with sarcoma, pancreatic cancer and NSCLC in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top